Literature DB >> 10781191

Optimising local therapy during oral surgery in patients with von Willebrand disease: effective results from a retrospective analysis of 63 cases.

A B Federici1, R Sacco, F Stabile, M Carpenedo, E Zingaro, P M Mannucci.   

Abstract

Bleeding after dental extractions is very frequent in patients with von Willebrand disease (vWD) and in the past often necessitated transfusions with factor VIII/von Willebrand factor concentrates (vWFc). To evaluate the benefits of a standard local therapy on bleeding complications during oral surgery, 63 consecutive patients with vWD were analysed retrospectively. All types of vWD were included: type 1 (n=31), type 2 (n=22) and type 3 (n=10). All the patients had dental extractions or periodontal surgery at the same hospital by the same oral surgeons. All cases had been given tranexamic acid (TA) before and for 7 days after surgery. As additional local therapy fibrin glue (FG) was used during surgery in several patients. Additional systemic therapies were: desmopressin (DDAVP, 0.3 microg kg-1) and fVIII/vWF concentrates (vWFc, 40 U kg-1) given as a single dose before surgery. The 29 subjects (46%) treated locally did not bleed. Among the remaining cases, 24 (38%) were given DDAVP as additional systemic therapy and 6 (9.5%) received vWFc. There was bleeding after surgery in only two cases who had been given local FG (type 2 B) or systemic vWFc (type 3), but bleeding was stopped with an additional local application of FG. Our data suggest that a standard local therapy with TA and FG with DDAVP can prevent bleeding complications during oral surgery in the majority of patients (84%) with vWD and reduce the need for concentrates, with all their possible complications and high costs.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10781191     DOI: 10.1046/j.1365-2516.2000.00370.x

Source DB:  PubMed          Journal:  Haemophilia        ISSN: 1351-8216            Impact factor:   4.287


  10 in total

1.  [In vitro testing of thrombocyte adhesion to different collagenous hemostyptic agents].

Authors:  D Rothamel; F Schwarz; V Stoldt; M Herten; C Kotthaus; J Becker
Journal:  Mund Kiefer Gesichtschir       Date:  2006-05

2.  6 Factor VIII Concentrates, Factor VIII/von Willebrand Factor Concentrates, Factor IX Concentrates, Activated Prothrombin Complex Concentrates.

Authors: 
Journal:  Transfus Med Hemother       Date:  2009       Impact factor: 3.747

3.  ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease.

Authors:  Nathan T Connell; Veronica H Flood; Romina Brignardello-Petersen; Rezan Abdul-Kadir; Alice Arapshian; Susie Couper; Jean M Grow; Peter Kouides; Michael Laffan; Michelle Lavin; Frank W G Leebeek; Sarah H O'Brien; Margareth C Ozelo; Alberto Tosetto; Angela C Weyand; Paula D James; Mohamad A Kalot; Nedaa Husainat; Reem A Mustafa
Journal:  Blood Adv       Date:  2021-01-12

4.  Antifibrinolytic therapy for preventing oral bleeding in patients with haemophilia or Von Willebrand disease undergoing minor oral surgery or dental extractions.

Authors:  Karin Pm van Galen; Eveline T Engelen; Evelien P Mauser-Bunschoten; Robert Jj van Es; Roger Eg Schutgens
Journal:  Cochrane Database Syst Rev       Date:  2019-04-19

Review 5.  Surgical prophylaxis in von Willebrand's disease: a difficult balance to manage.

Authors:  Massimo Franchini
Journal:  Blood Transfus       Date:  2008-09       Impact factor: 3.443

Review 6.  A benefit-risk review of systemic haemostatic agents: part 1: in major surgery.

Authors:  Ian S Fraser; Robert J Porte; Peter A Kouides; Andrea S Lukes
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

7.  Von Willebrand disease: an overview.

Authors:  K Pavani Bharati; U Ram Prashanth
Journal:  Indian J Pharm Sci       Date:  2011-01       Impact factor: 0.975

8.  Hematological evaluation of acquired von Willebrand syndrome before oral surgery: Management of an unusual case.

Authors:  Gian P Bombeccari; Gianpaolo Guzzi; Paolo Bucciarelli; Francesco Pallotti; Francesco Spadari
Journal:  Asian J Transfus Sci       Date:  2012-01

9.  The Effectiveness of a New Hemostatic Agent (Ankaferd Blood Stopper) for the Control of Bleeding following Tooth Extraction in Hemophilia: A Controlled Clinical Trial.

Authors:  Hakkı Oğuz Kazancıoğlu; Onur Cakır; Gülsüm Ak; Bülent Zülfikar
Journal:  Turk J Haematol       Date:  2013-03-05       Impact factor: 1.831

10.  Dental invasive procedures in von Willebrand disease outpatients treated with high purity FVIII/VWF complex concentrate (Fanhdi®): experience of a single center.

Authors:  Valeria De Padua; Umberto Romeo; Cristina Santoro; Riccardo Bosco; Erminia Baldacci; Antonietta Ferretti; Francesco Malaspina; Maria Gabriella Mazzucconi; Domenico Gaglioti
Journal:  Heliyon       Date:  2020-02-25
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.